The QualityStocks Daily Friday, June 16th, 2023

Today's Top 3 Investment Newsletters

QualityStocks(MAPT) $0.0007 +133.33%

StockEarnings(MGAM) $0.6551 +24.85%

Schaeffer's(IRBT) $51.0000 +21.20%

The QualityStocks Daily Stock List

Scworx (WORX)

QualityStocks, StockMarketWatch, MarketClub Analysis, BUYINS.NET, Jet-Life Penny Stocks, InvestorPlace and TradersPro reported earlier on Scworx (WORX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Scworx Corp. (NASDAQ: WORX) is engaged in the provision of software solutions for managing foundational business applications for health care providers in the U.S.

The firm has its headquarters in New York and was incorporated in 2012 by Marc C. Schessel. It operates in the consumer sector, under the consumer discretionary services industry and the leisure facilities and services sub-industry. The firm, which was known as Alliance MMA Inc., serves consumers in New York.

The enterprise provides different software services and solutions like a closed loop scanning solution known as ScanWorx; contract management, a module which helps healthcare providers in establishing contract management systems, rebate management and offers care to patients; CDM (Charge Description Master Management) module, which helps health care providers to integrate CDM data into the workflow of the purchasing system of a hospital; electronic medical record management; and virtualized item master automation, expansion and file repair.

Additionally, the firm also provides a ticketing platform that caters to the mixed martial arts industry dubbed CageTix. This is in addition to being involved in the sale of self-swab test kits for the coronavirus as well as personal protective equipment. It sells its services and solutions to health systems and hospitals via reseller and distribution partnerships.

The company recently appointed a new individual to its board of directors who has decades of experience in healthcare and will help the firm form partnerships with large hospital groups, which it targets. This is bound to bring in more investors into the firm, which will boost growth.

Scworx (WORX), closed Friday's trading session at $0.66, up 75.6721%, on 94,864,048 volume. The average volume for the last 3 months is 7.049M and the stock's 52-week low/high is $0.2021/$1.09.

Infinity Pharmaceuticals (INFI)

MarketBeat, StreetInsider,, The Street, SmarTrend Newsletters, StockMarketWatch, MarketClub Analysis, QualityStocks, Streetwise Reports, TraderPower, BUYINS.NET, Trades Of The Day, Market Intelligence Center Alert, TradingMarkets, Zacks, Seeking Alpha, Hit and Run Candle Sticks, InvestmentHouse, DrStockPick, Daily Trade Alert, CRWEWallStreet, BestOtc, PennyStockProphet, Hototc, Investing Futures, Investment House, InvestorPlace, Jason Bond, CRWEPicks, Market FN, Buzz Stocks, Barchart, Greenbackers, Promotion Stock Secrets, Weekly Wizards, Wealth Daily, Wall Street Mover, Trading Markets, TradersPro, The Best Newsletters, StockOnion, StockHotTips, SmallCapVoice, PennyOmega, Schaeffer's, Millennium-Traders, Profitable Trader Authority, PoliticsAndMyPortfolio, PennyToBuck, PennyStockScholar, PennyPro, AllPennyStocks, Penny Pick Finders, OTCtipReporter, Money Wealth Matters and SmallCap Network reported earlier on Infinity Pharmaceuticals (INFI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (FRA: I3F) is a biopharmaceutical firm that is engaged in the discovery and development of new medications for cancer.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 1995, on March 22nd by Steven H. Holtzman. It serves consumers in the U.S. and operates as part of the pharmaceutical manufacturing industry, under the healthcare sector.

The company is party to collaboration agreements with Bristol Myers Squibb Company, F. Hoffman-La Roche Ltd and Arcus Biosciences Inc., and it has a strategic alliance with PellePharm Inc. which entails the development and commercialization of rights to its IPI-926 inhibitor program. It also has a strategic alliance with Verastem Inc., for the development, commercialization and manufacture of duvelisib and formulations which contain duvelisib; and another alliance with Intellikine Inc., entailing the discovery, development and commercialization of pharmaceutical products which target the gamma and/or delta isoforms of P13K.

The enterprise uses small molecule drug technologies to develop its products. Its product pipeline is made up of an orally administered clinical-stage immune-oncology product candidate known as IPI-549, which inhibits the phosphoinositide-3-kinase-gamma enzyme. The formulation is currently undergoing a phase 1/1b clinical trials evaluating its effectiveness in treating ovarian cancer, solid tumors and triple negative breast cancer.

The firm recently reported data from its IPI-549 trial, which shows that the formulation improves outcomes for patients with 2 distinct cancer types. The success of this formulation will not only greatly benefit patients suffering from triple negative breast cancer and metastatic urothelial cancer, but also bring in more investors into the firm, which will have a positive effect on the company’s growth.

Infinity Pharmaceuticals (INFI), closed Friday's trading session at $0.238, up 32.5905%, on 7,049,065 volume. The average volume for the last 3 months is 163.227M and the stock's 52-week low/high is $0.119/$1.76.

Evelo Biosciences Inc. (EVLO)

MarketBeat, StockMarketWatch, QualityStocks, BUYINS.NET, Trades Of The Day, StreetInsider, The Street, StockEarnings, Money Wealth Matters, FreeRealTime and Daily Trade Alert reported earlier on Evelo Biosciences Inc. (EVLO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Evelo Biosciences Inc. (NASDAQ: EVLO) is a biotechnology firm that is engaged in the discovery and development of oral biologics for the treatment of cancer and inflammatory ailments.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 2014 by David A. Berry and Noubar B. Afeyan. It operates as part of the scientific research and development services industry, under the healthcare sector. It serves consumers in the United States and has two companies in its corporate family.

The company’s aim is to improve the lives of patients around the globe through the development of new therapies for various indications. It is pioneering the development of a new class of medications for the treatment of cancer, neuro-inflammatory, neurological, metabolic, immune-inflammatory and autoimmune ailments.

The enterprise’s product pipeline comprises of a formulation for oncology dubbed EDP1908; an extracellular vesicle investigational biologic dubbed EDP2939, which is indicated for the treatment of inflammatory ailments; and an inactivated oral biologic known as EDP1867 which has been developed to treat inflammatory ailments. In addition to this, the enterprise is involved in the development of a microbe candidate dubbed EDP1815, which is also indicated for the treatment of inflammatory illnesses. This formulation is currently undergoing a clinical development trial evaluating its effectiveness in treating atopic dermatitis and psoriasis, as well as the hyper-inflammatory response linked to the coronavirus.

The firm announced positive data from its EDP1815 clinical development trial for psoriasis, which brings them one step closer to addressing the unmet needs of millions of patients living with the ailment. The success and approval of this drug will help bring in more investors into the firm as well as boost its growth.

Evelo Biosciences Inc. (EVLO), closed Friday's trading session at $0.12, up 44.7527%, on 163,227,318 volume. The average volume for the last 3 months is 129,461 and the stock's 52-week low/high is $0.0243/$3.29.

iPower Inc. (IPW)

QualityStocks, Trades Of The Day, StocksEarning and MarketBeat reported earlier on iPower Inc. (IPW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

iPower Inc. (NASDAQ: IPW) is an online hydroponic equipment supplier that is engaged in the provision of hydroponics equipment online.

The firm has its headquarters in Duarte, California and was incorporated in 2018, on April 11th by Allan Huang and Chenlong Tan. Prior to its name change in September 2020, the firm was known as BZRTH Inc. It serves consumers around the globe.

The company operates and owns the retail website, where it sells over 23,000 stock keeping units as well as other products, which allow consumers to grow flowers, fruits and vegetables, as well as other plants like marijuana. It also leases about 72,000 ft2 of floor area space across a pair of fulfillment centers in California.

The enterprise’s products include pumps, trimming machines, hydroponic water-resistant grow tents, growing media, nutrients, activated carbon filters, ventilation systems, greenhouse and advanced indoor grow-light systems and accessories for hydroponic gardening, as well as other outdoor and indoor growing products under the Simple Deluxe and iPower brands. The enterprise provides roughly 3,000 private label products which are marketed under the aforementioned brands. In addition to selling its products through its website, it sells its products via 3rd party e-commerce channels like Amazon.

The firm recently launched a new line of advanced nutrient products dubbed Flourish. This move will positively affect margin expansion for the firm but also bring in more revenue into the company. This is in addition to extending its consumer reach through the use of Amazon, which is available globally.

iPower Inc. (IPW), closed Friday's trading session at $1.4, up 32.0755%, on 129,461 volume. The average volume for the last 3 months is 3.563M and the stock's 52-week low/high is $0.35/$1.40.

Sientra Inc. (SIEN)

MarketBeat, Jason Bond, StreetInsider, BUYINS.NET, Barchart, MarketClub Analysis, StockMarketWatch, QualityStocks, TraderPower, Hit and Run Candle Sticks, Daily Trade Alert, Trades Of The Day,, Schaeffer's, Trading Concepts, The Street, InvestorsUnderground, Investing Futures and Market Report reported earlier on Sientra Inc. (SIEN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sientra Inc. (NASDAQ: SIEN) (FRA: S0Z) is a medical aesthetic firm that is focused on the development and sale of medical aesthetic products to plastic surgeons.

The firm has its headquarters in Santa Barbara, California and was incorporated in 2003, on August 29th by Hani M. Zeini. Prior to its name change in April 2007, the firm was known as Juliet Medical Inc. It operates as part of the medical equipment and supplies manufacturing industry, under the health care sector. The firm has six companies in its corporate family and serves consumers around the globe, with a focus on the United States.

The company is focused on developing aesthetics medicine and plastic surgery cosmetic and reconstructive surgical devices, which include body contouring implants, facial and nasal implants, and saline-filled breast implant sizers, among other specialty products.

The enterprise operates through the miraDry and Breast products segments. The miraDry segment is focused on the sale of the non-surgical miraDry system, which is made up of a handheld device and console that uses single-use consumable bioTips. The system is used to permanently reduce underarm sweat, odor and hair. On the other hand, the breast products segment is focused on the sale of scar management products, tissue expanders and breast implants, under the Biocorneum, Softspan, Dermaspan, AlloX2 and Sientra brands.

The company recently acquired fat grafting technology from Auragen Aesthetics. This move will help broaden its position in the plastic surgery market, with short-term growth opportunities in breast reconstruction and augmentation and long-term opportunities in new aesthetic applications. This move adequately positions the company to capitalize on the plastic surgery market in the U.S., which will be good for its revenue as well as its growth.

Sientra Inc. (SIEN), closed Friday's trading session at $2.31, up 30.5085%, on 3,562,756 volume. The average volume for the last 3 months is 303.685M and the stock's 52-week low/high is $1.25/$16.50.

Maptelligent Inc. (MAPT)

We reported earlier on Maptelligent Inc. (MAPT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Maptelligent Inc. (OTC: MAPT) is focused on the provision of a cloud-based geographic platform which integrates data from alarms, cameras, sensors and accountability systems to develop actionable intelligence on an intuitive map display.

The firm has its headquarters in Henderson, Nevada and was incorporated in 1974, on August 7th. The firm serves consumers around the globe.

The company is party to a strategic partnership with NSION Technologies, which entails providing secure situational awareness using IoT sensors and real time video data streaming technology.

The enterprise’s platform also offers access information relevant to sites and structures that improve situational awareness and emergency response. It also offers a suite of applications and maps which afford consumers the ability to manage and maintain data in a mobile environment. For instance, building engineers can use the platform to manage maintenance schedules for elements like extinguishers, pull stations and alarm panels, which require regular attention, as well as public safety to develop incident preplans associated with building floor plans. In addition to this, the enterprise provides a cloud content management solution which manages and stores data associated with security solutions, professional services for safety assessments and system integration services. It serves various entities and organizations which are at risk from emergency incidents and threats like hospitals, schools universities, ports and shopping malls.

The company recently entered into a partnership with the Interactive Tactical Group, which will provide a range of services to the company’s clients as well as more accurate and reliable information in the indoor mapping capability space to consumers. This will be good for its investments as well as its growth.

Maptelligent Inc. (MAPT), closed Friday's trading session at $0.0007, up 133.3333%, on 303,684,802 volume. The average volume for the last 3 months is 3,080 and the stock's 52-week low/high is $0.0002/$0.00195.

G2 Goldfields (GUYGF)

We reported earlier on G2 Goldfields (GUYGF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

G2 Goldfields Inc. (OTCQX: GUYGF) (CVE: GTWO) is a mining firm focused on acquiring and exploring for gold deposits in Guiana.

The firm has its headquarters in Toronto, Canada and was incorporated in 2009, on May 21st by Dean G. Macachern. It operates as part of the gold industry, under the basic materials sector. The firm serves consumers around the globe.

The company operates primarily in Guyana, where it owns a 100% interest in two past gold-producing mines. Its projects include the Sandy Lake Gold Project in Canada, Puruni, Aremu / Oko Gold Project in Guyana; and Peters Mine in Guyana. The Oko project is situated in the southeastern portion of the Cuyuni Mining District, approximately 120 km west-southwest of Guyana’s capital city, Georgetown, 60 km west of the town of Bartica, and directly north of Reunion Gold’s Oko West project. It covers approximately 19,200-acres of land. The project covers approximately 7,149 hectares of land, covering across 17km of prospective strike length. Its Puruni project has two properties, Peter and Jubilee mines. The property is situated to the southwest of G2’s Oko-Aremu property, the Peters Mine and Jubilee Mine. The Jubilee Mine is situated approximately 4km southeast of the Peters Mine property.

The enterprise, which recently expanded drilling at its Oko project, remains focused on expanding its resource, accelerating its growth and generating value for its shareholders. This will, in turn, bring in additional revenues and investments into the firm.

G2 Goldfields (GUYGF), closed Friday's trading session at $0.6379, even for the day. The average volume for the last 3 months is 2,946 and the stock's 52-week low/high is $0.3975/$0.7004.


Real Pennies reported earlier on IXICO PLC (PHYOF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

IXICO Plc (OTC: PHYOF) (LON: IXI) (FRA: PYPB) is a company engaged in the provision of data analytics services to the biopharmaceutical industry.

The firm has its headquarters in London, the United Kingdom and was incorporated in 1995, on November 28th by Derek Lionel Glendon Hill. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe, with a focus on those in Switzerland, the United Kingdom, Ireland, the Netherlands, the United States and the rest of Europe.

The enterprise’s services include collection, analysis, management, and reporting on data generated in the course of a clinical study. Its technologies comprise TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer; and Assessa, a secure online digital platform that offers clinical decision support for patient selection and post-marketing surveillance. In addition, the enterprise focuses on therapeutic areas that include Parkinson's, Alzheimer's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and other rare neurological diseases. Further, the enterprise engages in data collection and analysis of neurological disorders; offers drug development analytics, imaging operation services, and post-marketing surveillance services, as well as consultancy services; and offers end-to-end services, such as trial design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and navigating the regulatory pathway.

The company is focused on transforming the advancement of investigation therapies for neurological illnesses, a move whose success will greatly influence the company’s growth.

IXICO PLC (PHYOF), closed Friday's trading session at $0.3, even for the day. The average volume for the last 3 months is 1 and the stock's 52-week low/high is $0.003/$0.77.

Borussia Dortmund (BORUF)

MarketBeat reported earlier on Borussia Dortmund (BORUF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Borussia Dortmund GmbH & Co KGaA (OTC: BORUF) (ETR: BVB) (FRA: BVB) (SWX: BVB) (VIE: BVB) is a football club and a professional football squad.

The firm has its headquarters in Dortmund, Germany and was incorporated in 1909, on December 19th. It operates as part of the entertainment industry, under the communication services sector. The firm mainly serves consumers in Germany.

The company operates through the Borussia Dortmund GmbH & Co. KGaA, BVB Merchandising GmbH, BVB Event & Catering GmbH, and best-travel Dortmund GmbH segments. The Borussia Dortmund GmbH & Co. KGaA segment manages a football club including a professional football squad and includes revenue arising from transfer deals, catering, TV marketing, advertising, and match operations. The BVB Merchandising GmbH segment comprises of the firm’s merchandising business. The BVB Event & Catering GmbH segment engages in conducting stadium tours; providing and arranging for event staffing services; and planning, organizing, catering, steering, and conducting events of all types. The best-travel Dortmund GmbH segment relates to arranging travel by air, rail and ship, as well as package tours offered to private customers by travel agents.

The enterprise is involved in operating a football club in Dortmund and marketing SIGNAL IDUNA PARK. It conducts stadium tours, sports travel, conferences, incentive trips, and various other events; sells merchandise; offers arrangements for event staffing services, and hotel and car hire bookings; and provides travel services by air, ship, and rail, as well as package tours.

The company remains focused on better meeting consumer needs and generating value for its shareholders.

Borussia Dortmund (BORUF), closed Friday's trading session at $4.71, even for the day. The average volume for the last 3 months is 3 and the stock's 52-week low/high is $2.82/$6.32.

Heyu Biological Technology (HYBT)

We reported earlier on Heyu Biological Technology (HYBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Heyu Biological Technology Corporation (OTC: HYBT) is a company focused on researching, developing and manufacturing healthcare equipment.

The firm has its headquarters in Xiamen, China and was incorporated in 1987, on May 18th. Prior to its name change in June 2018, the firm was known as Pacific WebWorks Inc. It operates as part of the medical devices industry, under the healthcare sector. The firm mainly serves consumers in the People’s Republic of China and the United States.

The company is focused on the development of Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber, a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber. Its business units include Pacific Web Works, Headlamp Ventures, IntelliPay, TradeWorks, Thrifty Seeker, Promontory Marketing, World Commerce Network and Dynamic WebTools. The company focuses on the credit card transaction processing business. The firm is also focusing on developing its internet technologies. IntelliPay Inc. is a developer and provider of transaction processing and payment products for various businesses. Visual WebTools Software allows users to create and manage a business on the internet. Headlamp Ventures is a venture capital investment business. Tradeworks Marketing is a merchant processing business. Asher Gloves is a developer of gloves for golf and various industries.

The enterprise remains focused on advancing the development of its equipment, creating shareholder value and bolstering its overall growth, a move that will encourage investments into the firm.

Heyu Biological Technology (HYBT), closed Friday's trading session at $0.2, even for the day, on 3 volume. The average volume for the last 3 months is 4,000 and the stock's 52-week low/high is $0.0004/$0.25.

Lonking Holdings (LONKF)

MarketBeat reported earlier on Lonking Holdings (LONKF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lonking Holdings Ltd (OTC: LONKF) (OTC: LKHLY) (HKG: 3339) (FRA: C91B) is an investment holding firm that is focused on the manufacture and distribution of wheel loaders, road rollers, forklifts, excavators and other construction machinery in Mainland China.

The firm has its headquarters in Shanghai, China and was incorporated in 1993. It operates as part of the farm and heavy construction machinery industry, under the industrials sector. The firm serves consumers in the People's Republic of China.

The company operates through the Sale of Construction Machinery, Finance Lease of Construction Machinery, and Financial Investment segments. Its principal subsidiaries include Lonking Shanghai Machinery Co. Ltd; Lonking (Shanghai) Precision Hydraulic Component Co. Ltd; and Lonking Fujian Machinery Co. Ltd. The majority of sales are derived from China. Through its subsidiaries, the company is also involved in the manufacture and distribution of axles and gear boxes.

The enterprise also offers skid steer loaders; and diesel and electric forklifts. In addition to this, it provides components, such as axles, gear boxes, cylinders, gears, castings, and high-end hydraulic pumps and valves. Further, the enterprise offers finance leasing for wheel loaders and other machinery. It also sells its products to approximately 40 countries in Mid and South America, Asia and Pacific area, Mid-East countries and Africa, and internationally.

The firm remains committed to extending its consumer reach, a move that will in turn bring in additional revenues and investments into the firm. This is in addition to bolstering its overall growth.

Lonking Holdings (LONKF), closed Friday's trading session at $0.157, even for the day. The average volume for the last 3 months is 18.68M and the stock's 52-week low/high is $0.1399/$0.20.

Riot Blockchain Inc. (RIOT)

Schaeffer's, MarketClub Analysis, StocksEarning, InvestorPlace, StockMarketWatch, QualityStocks, MarketBeat, TradersPro, Market Intelligence Center Alert, The Street, INO Market Report, Zacks, The Online Investor, Kiplinger Today, AllPennyStocks, Trades Of The Day, TraderPower, BUYINS.NET, InvestorsUnderground, Daily Trade Alert, StockEarnings, PennyStockLocks, Early Bird, BillionDollarClub, Market Intelligence Center, Penny Stock 101, StockRockandRoll, StreetAuthority Daily, Trading Tips, Louis Navellier, Money Morning, Investors Alley, StreetInsider, The Daily Market Alert, TopPennyStockMovers and Promotion Stock Secrets reported earlier on Riot Blockchain Inc. (RIOT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

This week marked a period of relative stability in the cryptocurrency market, as prices showed signs of steadying after a significant sell-off triggered by legal actions from the U.S. Securities and Exchange Commission (SEC) against Binance and Coinbase for violating securities regulations.

According to Coin Metrics, Cardano’s ADA coin remained unchanged on Monday, following a brief weekend tumble of approximately 17%. Conversely, Solana’s SOL recorded a 6% decline, while Polygon’s MATIC experienced a drop of more than 2%. During the weekend, both Polygon and Solana saw substantial declines of around 20% and 17%, respectively. Binance’s BNB remained relatively stable over the weekend but encountered a loss of more than 3% on Monday.

Over the past week, numerous alternative coins (altcoins) experienced significant drops, with some plunging by at least 15%. In the seven-day period ending on June 9, 2023, Cardano’s coin fell by 27%, Solana’s saw a 23% decrease, Polygon’s tumbled by 24%, and the BNB token dropped more than 18%.

Last week, the SEC filed lawsuits against Binance and Coinbase, alleging that both platforms had operated as exchanges, broke dealers or clearing agencies without proper registration and had also engaged in the sale of unregistered securities. The agency specifically identified Polygon, Solana and Cardano coins as potential securities. Consequently, the trading app Robinhood delisted these three coins on Friday.

In the lawsuit against Binance, the SEC charged the company and Binance CEO Changpeng Zhao with misrepresenting trade volumes, misusing customer cash and deceiving customers about its internal controls.

Meanwhile, the price of ether and Bitcoin remained comparatively constant, barely moving from the flat line. The support from the February high, according to Bitbank’s crypto market analyst Yuya Hasegawa, helped to keep Bitcoin’s slide in check when compared to other cryptocurrencies. Hasegawa cautioned, however, that Bitcoin would have a perilous week as more troubling information about the SEC’s legal proceedings could surface as the wider financial markets look forward to the U.S. FOMC and CPI meeting.

Following the filing of the lawsuits, SEC Chairman Gary Gensler said in an interview with CNBC that the country did not need additional digital currencies. He argued that U.S. securities regulations should benefit investors and emphasized that the cryptocurrency sector should conform to the same standards, requiring platforms and intermediaries to comply.

President Joe Biden appointed Gensler in 2021, and Gensler has spent a significant portion of the previous year taking action against cryptocurrency businesses and exchanges.

The signs of stability being seen in the crypto market are welcome news to industry players such as Riot Blockchain Inc. (NASDAQ: RIOT) that are seeking to deepen their penetration in the U.S. market and elsewhere.

Riot Blockchain Inc. (RIOT), closed Friday's trading session at $10.4, up 4.3129%, on 18,679,714 volume. The average volume for the last 3 months is 135,959 and the stock's 52-week low/high is $3.25/$14.4292.

The QualityStocks Company Corner

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)

The QualityStocks Daily Newsletter would like to spotlight Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF).

After a year or so of relatively lackluster performance, the gold market surged in 2022 as several countries significantly increased their gold purchases as part of efforts to build up their reserves. By the time 2022 drew to a close, central banks around the world had purchased a whopping 1,136 tons of gold, pumping around $70 billion into the market. China's central bank was among the largest buyers of gold through 2022 and into 2023, buying nearly one-half of the global gold purchases in 2022 (522 tons) and 244 tons in January and February. Beijing has increased its gold purchases repeatedly over the course of the year, adding an additional 19 tons of gold in May to bring its total gold stockpile to 2,092 tons. Like several other major central banks, the People's Bank of China has increased its gold holdings for several months in a row amid surging rates of global inflation and a volatile geopolitical environment. The surge in global gold purchases is also partly due to declining trust in the U.S. dollar among economies such as China and Russia. As different countries move to bolster their gold holdings, enterprises such as Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) are likely to be encouraged by the favorable market conditions and ramp up their programs to bring more gold onto the market.

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County.

The company in October 2022 received permit approval from the Bureau of Land Management (BLM) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023.

The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit.

Arizona Metals Corp. is based in Toronto, Canada.


Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing.

The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices.

Management Team

Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada.

David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School.

Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services.

Vision Energy Corp. (OTCQX: AZMCF), closed Friday's trading session at $2.58, up 4.2424%, on 135,959 volume. The average volume for the last 3 months is 58,338 and the stock's 52-week low/high is $2.30/$4.04.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

The European Alliance of Associations for Rheumatology has reported an influx in the prevalence of auto-inflammatory and autoimmune diseases. Autoimmune conditions are diseases that occur when the body's immune system mistakes healthy tissues for harmful cells and attacks normal cells. There is currently no cure for autoimmune diseases, but patients can use various treatments to manage the conditions and minimize organ damage. Although the association posits that the increase in autoimmune cases may be due to environmental factors, researchers don't have enough data to come to a concrete conclusion. A team of researchers from the EULAR analyzed nearly 20 of the most common autoimmune disorders to fill up this information gap. They assessed autoimmunity trends over time and by age, sex, region, season and socioeconomic status. The research team then used health data collected from 22 million United Kingdom citizens to calculate the prevalence and incidence rate of autoimmune diseases before modeling variation and temporal trends. The data showed that autoimmune diseases had a prevalence rate of 7.4% in men and 13.1% in women, with a general prevalence rate of 10%. The researchers noted that incidence rates went up by 4% from 2000 to 2019 in both men and women. Many companies such as BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) are rising up to the challenge and developing treatments aimed at addressing the clinical needs of patients diagnosed with autoimmune conditions so that those individuals can enjoy a better quality of life or even reverse the progression of the diseases.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Friday's trading session at $1.46, up 5.036%, on 58,338 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.04/$.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is releasing additional findings from its DIAB-A22-1 study, a diabetes animal study designed to evaluate the company's proprietary DehydraTECH-CBD. DehydraTECH is a patented drug-delivery formulation and processing platform technology developed by Lexaria. The company noted that in addition to the three positive outcomes reported earlier — weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels — the study has indicated a reduction in blood glucose levels and improvements in kidney function. These results were gathered after the company undertook a further round of analysis to explore additional study outcomes; the additional analysis included using an alternate blood glucose assay detection system with higher detection sensitivity. The company also reported updates on two of its applied R&D programs:DEM-A22-1 and EPIL-A21-1. Lexaria's DEM-A22-1 is a study designed to investigate whether DehydraTECH-CBD enables any procognitive performance enhancements with potential use in dementia treatment.

The company noted that the findings from this study were "generally unremarkable and several unexpected study complications may have muted efficacy distinction ability." The EPIL-A21-1 was designed to evaluate the effectiveness of LEXX's DehydraTECH-CBD compared to one of the world's leading anti-seizure medications, Epidiolex(R), in reducing seizure activity. Initial findings from the study seemed to demonstrate that DehydraTECH-CBD had effectiveness at lower doses and with greater rapidity than Epidiolex. In the past few months, Lexaria has also completed a final study under its EPIL-A21-1 program that looked at establishing dosage amounts. "This ED50 study was designed with an objective to hopefully corroborate Lexaria's prior MES experimental findings," the company states in the press release. "Lexaria is pleased to confirm that the outcome demonstrated that DehydraTECH-CBD was most effective at a dose of 75 mg/Kg, also as previously reported from the initial round of work in this animal model, which compared favorably to Epidiolex that generally required a higher dose of 100 mg/Kg to achieve comparable findings."

To view the full press release, visit

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $0.7, up 1.4199%, on 273,736 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6488/$3.60.

Recent News

IGC Pharma Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight IGC Pharma Inc. (NYSE American: IGC).

Thai Ganja TV has been a platform where marijuana enthusiasts have closely followed the remarkable transformation of the drug from being a banned substance to a legalized medicinal plant and eventually a recreational indulgence. However, a year after the decriminalization of cannabis in Thailand, the platform's approximately 90,000 followers are now witnessing with bemusement the threats from rival politicians who seek to once again outlaw or strictly regulate open consumption and dispensaries. At the forefront of this debate is the soon-to-be prime minister, Pita Limjaroenrat, whose party MFP surprisingly emerged as the winner in the May 14, 2023, general elections. Although MFP is generally seen as the most progressive political party in Thailand, marijuana advocates argue that it is spearheading the movement to curtail recreational use, casting a shadow over the nation's multibillion-dollar marijuana industry. The regulatory uncertainty seen in the marijuana industry around the world has created an opportunity for enterprises such as IGC Pharma Inc. (NYSE American: IGC) to develop medicines from marijuana. These entities plan on getting FDA approval for those therapeutics so that patients can easily access the novel treatments sans fearing that they could run afoul of prohibitive laws or complex state-level marijuana regulations.

IGC Pharma Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

IGC Pharma Inc. (NYSE American: IGC), closed Friday's trading session at $0.31, up 3.4023%, on 80,313 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$0.74.

Recent News

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF).

The graphite supply chain is geographically concentrated with nearly 65% of output currently produced in China

The U.S. pursued to promote further investment and geographical diversification within the sector, with credits granted to electric vehicles produced with critical minerals that are not supplied by ‘foreign entities of concern'

Reflex Advanced Materials are working towards demonstrating the positive economics of the past producing, Ruby Graphite mine in Montana, USA

The company recently revealed that they are in talks with prospective North American customers and are beginning the material qualification programs for end use potential offtake clients down the line

A battery's anode is a crucial component of its design, responsible for receiving incoming electricity and dissipating the heat created in the process of doing so; notably, it is also almost entirely made up of graphite. Today, the world is almost entirely dependent on China for its graphite supply – the nation mines 65% of the world's graphite, processes 85 percent and is home to the world's sixth largest anode material producers, according to the International Energy Agency ( Mozambique is the world's second largest producer of the mineral, set to account for nearly 14% of global supply by 2030 according to Benchmark Minerals; nevertheless, 96% of Mozambican graphite is mined from the country's Cabo Delgado province, a geographical territory that has seen a huge rise in insurgent activity since 2017 ( With the natural graphite demand set to treble over the next four years as sales of electric vehicles soar, the constrained nature of the western supply chain of the essential mineral is becoming increasingly apparent. Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF), a British Columbia-based strategic minerals company focused on locating and developing economic properties within the advanced materials space, has centred its corporate mission around catering to the burgeoning need for natural graphite supply through its flagship asset the Ruby Graphite Project. One of a handful of companies comprising the western natural graphite supply chain, Reflex Advanced Material's flagship project is a past producing graphite mine in southwest Montana which produced upwards of 2,400 tons of graphite between 1902 and 1948, as well as the Ontario-based Zig Zag Lithium Property, encompassing eight mining claims across 2,710 hectares.

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.


Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Friday's trading session at $0.28, up 2.1898%, on 271,505 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.15/$0.765.

Recent News

CISO Global, Inc. (NASDAQ: CISO)

The QualityStocks Daily Newsletter would like to spotlight CISO Global, Inc. (NASDAQ: CISO).

CISO Global (NASDAQ: CISO), an industry leading cybersecurity and compliance provider, was featured in a recent equity research report published by Cantor Fitzgerald. The report, titled "Consistent 1Q23 Execution Adjusting for Non-Cash Related Charges/Noise," adjusts Cantor's 12-month price target to $1 from $2 due to volatile trading conditions while emphasizing CISO's consistent business execution and its solid start to 2023.

The publication reads, "As the focus in 2023 is on profitable growth, free cash flow was at -$2.3M, an improvement of over half a million dollars q/q and by +$800K better versus 1Q22. We attribute the FCF improvement realized to efficiency optimization on the best-in-class operations team, in our view. Deferred revenue growth continued on its accelerating path expanding >1.1x y/y to clear $4 million again, an indication the company is making headway into the large enterprise accounts. The cybersecurity talent labor imbalance continues to pivot to a shortfall, and the condition has not materially improved since last year, as we expected it would. The industry secular tailwind is supporting strong fundamentals in a recurring revenue rate of >62% on a TTM basis and a new logo retention rate of over 90%. On balance, we believe team CISO Global is starting 2023 in consistent execution despite the ongoing macro challenges and volatile trading conditions impacting the general software sector; however, we envision the company will accelerate at a healthy pace of 40-50% organically through 2023-24."

To view the full report, visit

CISO Global, Inc. (NASDAQ: CISO) is an industry leader in cybersecurity and compliance services. The company leverages an integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. Pulling disparate technologies, teams, and vendors together, CISO helps its clients enjoy a simpler and more successful journey to cyber resilience. Since 2019, CISO Global has worked to rapidly expand by acquiring world-class cybersecurity and compliance businesses with top-tier talent who utilize the latest technology to create innovative protection solutions.

The CISO Global workforce is comprised of cybersecurity experts spanning not only global geographies, but also specialties, industries, regulatory frameworks and focus areas. Its team includes audit and compliance specialists, certified forensics experts, ethical hackers, IEEE® certified biometric professionals, security engineers, around-the-clock analysts, and more – all backed by the most respected credentials in the industry. On an ongoing basis, the company works to identify cyber talent that is culturally aligned and that offers operating leverage through both existing customer revenue and relationships.

CISO Global has invested in enterprise solutions and executive talent to integrate its different organizations into an ecosystem that works together to provide complete cybersecurity through cross-pollination of solutions that begin at the network level and extend through technologies, people, policy, and practices. This ecosystem is intended to foster additional growth opportunities and drive overall recurring revenue. Once engaged, the company strives to become trusted advisors for customers’ cybersecurity and compliance demands by providing tailored security solutions based upon their organizational needs.

While cyber resilience requires cycles of continuous improvement, it is a journey that few in the current business and security climate seem to understand. With its deep bench of seasoned experts, CISO Global works to simplify that journey for its growing customer base, straightening out the curves and speeding up the process to resilience along the way.

Cybersecurity is a Culture, Not a Product

Integrating compliance and security, including principles of security by design, CISO Global helps its clients create an organization-wide culture of cybersecurity. Its offerings include audit and compliance, security operations center services, security engineering, virtual Chief Information Security Officer services, incident response, certified forensics, technical assessments and cybersecurity training.

In contrast to the majority of cybersecurity firms that specialize in a specific technology or service, CISO Global seeks to differentiate itself by remaining technology agnostic, focusing on accumulating highly sought-after subject matter experts. CISO Global believes that bringing together a world-class team of technological experts with multi-faceted proficiency in the critical aspects of cybersecurity is key to providing technology agnostic solutions to its clients in a business ecosystem that suffers from a chronic lack of highly skilled professionals.

CISO Global’s goal is to create a culture of security and to help quantify, define and capture a return on investment from information technology and cybersecurity spending. Its end-to-end, holistic process covers every aspect of clients’ cybersecurity and compliance requirements in an effort to promote greater efficiency and strengthen awareness about the integral role of internal team members in the cybersecurity culture of an organization.

As a result of this strategy, CISO Global customers receive an efficient engagement from a single partner that covers a wide range of their needs – addressing challenges more thoroughly and resolving problems more rapidly when compared to working with a host of vendors.

Market Outlook

According to an analysis by the firm Research and Markets, the global managed security services market was valued at $22.45 billion in 2020 and is projected to reach $77.01 billion by 2030, growing at a CAGR of 12.8% through the forecast period.

An expected increase in cybercrime, cost effectiveness of provided solutions and stringent mandatory government regulations aimed at protecting corporate data will drive the global managed security services market for the foreseeable future.

In addition, the documented and growing use of mobile devices in the workplace and the rise in captured and stored digital data serve to fuel market growth. Moreover, growing awareness about the critical nature of data security, the growing importance of e-business and demand for customized services is expected to offer ample opportunities for expansion of the market during the forecast period.

Management Team

David Jemmett is CEO and founder of CISO Global. He has more than 35 years of executive management and technology experience with telecommunications, managed services, and cybersecurity consulting services. He previously held positions as CEO of GenResults, a leading provider of security consulting services and technology solutions, and as CTO and founder at ClearData Networks, a HIPAA-compliant HealthDATA cloud hosting platform.

Dave Bennett is COO at CISO Global. Since 2015, he has served on the President’s STEM Advisory Board of Grand Canyon University. Before joining CISO Global, he served as Chief Product Officer at Experian Health and as Senior Vice President, Product for Gainwell Technologies. He has also held positions as Vice President and Worldwide Head of Build, Healthcare and Life Sciences at DXC Technology, and as EVP, Product and Strategy at Orion Health.

Ashley Devoto is President and Chief Information Security Officer at CISO Global. Over the past 17 years, Devoto has worked with the cybersecurity elite to design, build, and operate world-class cybersecurity programs for large, diverse organizations in both government and commercial enterprises. Prior to joining CISO, Devoto served as CISO for Booz Allen Hamilton, as business information security officer (BISO) at Bank of America, and as a cyberspace operations officer in the United States Air Force.

Deb Smith is CFO at CISO Global. Prior to assuming that position, she was the company’s EVP, Finance and Accounting. She has also served as SVP, Global Accounting at International Cruise and Excursions Inc., and as Chief Accounting Officer for BeyondTrust, an information security software company. She has also held the positions of Corporate Controller at Aspect Software and Assistant Controller at JDA Software.

CISO Global, Inc. (NASDAQ: CISO), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

GolfLync Inc.

The QualityStocks Daily Newsletter would like to spotlight GolfLync Inc.

GolfLync, the company behind the GolfLync app – a social network for matching games and players, recently hit an incredible milestone of 17,000 downloads as of May 2023. "Dubbed ‘the social network for golfers,' GolfLync is committed to helping golfers looking to grow their network by offering a platform that opens them up to other players with similar interests and course preferences. The growth in app downloads indicates golf's growing popularity, especially in the United States. Since 2011, the United States golf industry has grown by 22% over the past 10 years, from $68.8 billion to $84 billion in 2023. In addition, currently, 27% of new golfers are Gen Z, aged between 18-34, with women representing 41% of all off-course golfers. Social media influencers around the game have played a key role in growing its popularity, and it is projected that by 2030, the golf products market alone will be valued at $10.1 billion, up from $6.9 billion in 2022," a recent article explains. "GolfLync understands this growing popularity and the growing demand for golf courses, golf buddies and the best overall golf experience. The company looks to tap into this demand with its one-of-a-kind app, in what is a first for the industry. With its built-in logic, the GolfLync app can link individuals based on their preferences, enabling a more fulfilling and engaging golf experience that helps to grow the sport and create a healthy community around it."

To view the full article, visit

GolfLync Inc. matches golfers looking for a game through the company’s smartphone app, GolfLync. The company bills GolfLync as “the social network for golfers,” matching golf games and players similar to the way a dating app matches those looking for romance.

The app allows like-minded golfers to connect for a game simply by logging in. GolfLync helps golfers who are looking to grow their golf network find other players with similar interests and on course preferences. Whether you have recently moved to a new area and are looking for new golfing buddies, travel frequently and would like to play a round of golf while on the road, or just want to meet new golfers in your area, GolfLync is your answer. Spouses who enjoy golfing together can find other golfing couples to tee it up with. For a regular group that finds itself unexpectedly down a player, GolfLync can help find that last-minute addition to complete the foursome.

The company is based in Scottsdale, Arizona.

GolfLync App

GolfLync was created for golfers of all skill levels and preferences to connect with compatible players of similar skill. Golfers can find a tee time through GolfLync, join existing tee times and create new leagues. The app allows golfers to meet fellow players before committing to spend four hours on the course with them. GolfLync allows users to find new golf friends based on their preferences, such as walking or riding a cart, listening to music, friendly wagering, imbibing a favorite beverage at the 19th Hole and more. GolfLync is available for both Android and iOS as a free download.

Download on Apple App Store   Get it on Google Play

Market Opportunity

According to a report by Statista, a leading provider of market and consumer data, in 2022, the number of people participating in golf in the United States reached 25.6 million, with 15.5 million additional players participating in off-course activities like driving ranges. In 2020, over 502 million rounds of golf were played in the U.S. alone. The game, traditionally dominated by male players, is changing, with increased interest from women golfers driven by social media influencers around the game.

Lumen Sports puts the total number of golf courses in the U.S. at more than 16,700. According to Lumen, about 75% of those are public courses open to all golfers, with the rest considered private golf clubs that require a membership.


Management Team

Noah DiPasquale is a co-founder and CEO of GolfLync Inc., leading the marketing and operations of the platform. He is also the founder and CEO of Epic Golf Club, a premier national membership and private golf society which partners with hundreds of top tier private golf clubs allowing Epic members access to their courses and recently founded the Epic Foundation, a Scottsdale-based 501c3. He holds a B.S. in Business Administration, Management and Operations from the W.A. Franke College of Business at Northern Arizona University and an MBA in Marketing from the University of Phoenix.

Michael Quiel is a co-founder of GolfLync Inc. and the President of the organization. He leads the application development and research teams. Michael understands how to build successful companies. His deep knowledge of investment banking, finance and building successful business partnerships is unparalleled. He’s an expert at capital formation and growth hacking companies. He has raised over $250 million in capital and taken multiple companies public.

Recent News


Fintech Ecosystem Development Corp. (NASDAQ: FEXD)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (OTCQB: FEXD).

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) continues to move forward with plans to offer a diverse portfolio of fintech-related products and services for consumers and businesses throughout the global financial ecosystem. "Digital money is replacing physical cash, with consumers able to buy products and services anywhere in the world and make payments across borders. FEXD is developing mobile transaction platforms and services that are helping implement the coming changes – especially in underserved and overlooked markets like rural areas and Asia, the Middle East, Africa, and Latin America. FEXD supports the United Nations' Sustainable Development Goal to reduce cross-border transaction costs from 7% to 3%. The company's use of advanced technology is lowering fintech costs and international fees for cross-border transactions," a recent article reads. "FEXD is committed to supporting the fintech and digital money processes in developing countries and cultures. Using its keen understanding of market needs in regions worldwide, the company is helping ensure humanity has a path forward from an unhygienic cash system – reducing poverty, improving the lives of the unbanked, offering securing and savings options for migrant workers, connecting families and communities, empowering charities and women, and educating underprivileged children."

To view the full article, visit

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) is a special purpose acquisition company (SPAC) formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector.

The company’s mission is to create and grow a global financial services ecosystem to address unmet mobile money needs in developing and industrialized countries and markets. FEXD plans to achieve this by acquiring and merging with financial technology pioneers that have the potential to help establish its global fintech ecosystem, and by continuing the development of proprietary technologies and applications to keep the company at the forefront of the cashless society market.

Digital money is replacing physical cash. Consumers can buy products and services from anywhere in the world and make payments across borders. Parents can send money to students studying in other countries. Migrant workers are sending money to families in developing nations. Rural villagers without banks can send and receive money using their smartphones. FEXD is developing mobile transaction platforms, applications and services that are helping to implement these changes.

The company plans to offer a diverse portfolio of products and services to consumers and businesses in the United States, South Asia, East Asia, Africa, Europe and Latin America. Its growth strategy includes acquisition, innovation and market development.

FEXD is a Delaware corporation based in Collegeville, Pennsylvania. The company was launched in May 2021 by a management team led by Dr. Saiful Khandaker that has extensive experience in developing and managing financial service platforms and applications, primarily in the mobile money sector. FEXD is sponsored by Revofast LLC.

Acquisition Targets

In September 2022, FEXD announced definitive agreements for business combinations with Rana Financial Inc., a Georgia corporation, and Mobitech International LLC (dba Afinoz), a limited liability company organized in the United Arab Emirates. The agreements call for Rana and Afinoz to become wholly owned subsidiaries of FEXD, with the combined company expected to continue trading on the Nasdaq under existing ticker symbol ‘FEXD’. The mergers are expected to close in Q2 2023.

Rana Financial

Rana Financial is a licensed money transfer company founded in 2009. Rana provides fast and affordable online and mobile transfer of funds between the U.S. and Latin America. Rana has been providing money transfer services in the U.S. market for 13 years and has 30,000 active users. Rana’s money transfer business grew to 200,000 transactions in 2021. The merger agreement values Rana at an implied $78 million enterprise value.

Mobitech International LLC

Mobitech International LLC (dba Afinoz) is an artificial intelligence-enabled digital lending platform used by India’s leading banks, non-banking financial companies and fintech loan providers. Afinoz’s fintech platform supports enterprises making loans primarily to middle- and working-class borrowers via its website or through its mobile phone application. Afinoz’s platform makes loans available and affordable to millions of Indian workers and unbanked users by providing access at a low cost. Afinoz’s platform has more than 50 lending partners, and its database of registered users in India includes more than two million individuals. The merger agreement values Afinoz at an implied $120 million enterprise value.

Market Opportunity

According to analysis by global market research firm Mordor Intelligence, the worldwide financial technology market is valued at approximately $194 billion in 2023 and is projected to grow to nearly $500 billion by 2028, representing a CAGR of 18.97% for the forecast period. According to the report, various financial crises and the COVID-19 pandemic have fueled consumer adoption of, and investor interest in, fintech over the past several years.

Management Team

Dr. Saiful Khandaker is Founder, CEO and President of FEXD. He is Group CEO and founder of FAMA Holdings Inc., a global developer of fintech platforms, applications and services based in the U.S. with offices in the U.K., India, Bangladesh and Zambia. He is currently leading the development of the FAMACASH™ network, a global fintech ecosystem to provide fast, affordable mobile money services in underserved countries such as Bangladesh. Before founding FAMA, Dr. Khandaker spent more than two decades leading the development of software solutions for Fortune 100 companies and startups. He also helped numerous clients modernize their fintech services as Chief Technology Officer at Mi3. He holds a Doctor of Management in Organizational Leadership, a Master of Science in Technology Management, and a Bachelor of Science in Computer Information Systems.

Jenny Junkeer is CFO at FEXD. She is a Chartered Accountant with over 17 years of experience. As CEO of Junkeer New Era Consulting, she leads a team specializing in helping companies launch and optimize business operations in fast-changing industries. She has extensive experience helping organizations scale operations to maximize value. She is an Adjunct Association Professor at Deakin University in Australia, a board member of the Global Health Initiative Foundation, and Director of Implementation at ConnectCV. She holds a Bachelor of Commerce Degree (Honors) from Monash University.

FingerMotion Inc. (FEXD), closed Friday's trading session at $10.54, even for the day, on 10 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $9.9701/$11.00.

Recent News

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

SideChannel (OTCQB: SDCH) is committed to helping small and medium-sized businesses ("SMBs") that are otherwise susceptible to new cybersecurity threats due to their limited resources for investing in cybersecurity systems, services and infrastructure. "As a company founded on the belief that all enterprises, big or small, deserve top-tier security guidance at a manageable cost, SideChannel is aware of how technically demanding current cybersecurity solutions are, particularly when factoring in the possibility of AI. In addition, it recognizes how involved these solutions can be and how these two aspects leave SMBs vulnerable to attacks. Through its team of virtual Chief Information Security Officers (‘vCISOs'), SideChannel is looking to make solutions more accessible and affordable to its target market, ultimately reducing the risks associated with sophisticated AI technologies and their potential use as cybersecurity weapons," a recent article reads. "SideChannel, through its vCISOs, offers an affordable yet powerful cybersecurity solution that gives SMBs peace of mind. Through this, the company plays an integral role in reducing vulnerabilities in complex cyber networks, allowing SMBs to conduct business safely and effectively."

To view the full article, visit

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.


Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.


Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Friday's trading session at $0.12, even for the day, on 15,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0402/$0.18.

Recent News

Electronic Servitor Publication Network Inc. (OTCQB: XESP)

The QualityStocks Daily Newsletter would like to spotlight Electronic Servitor Publication Network Inc. (OTCQB: XESP).

XESP's managed service offering drives growth through its proprietary smart technology stack, the Digital Engagement Engine(TM)

This technology allows complete control of content while optimizing reach and lift

XESP's ‘Growth as a Service' allows clients to focus on their brands, core product offerings, and content creation

B2B businesses have seen an increased demand for digital assistance, especially for customer-driven marketing and associated communications. Electronic Servitor Publication Network (OTCQB: XESP), a digital engagement and activation company, offers a managed service that provides digital engagement and activation solutions for companies seeking to enhance their growth. The company is changing the landscape of digital marketing for its clients with its proprietary technology, the Digital Engagement Engine(TM).

Electronic Servitor Publication Network Inc. (OTCQB: XESP) is a digital engagement company offering a managed service which provides digital activation and engagement solutions to companies that seek to optimize their growth. Its managed service is powered by a proven, proprietary technology – the Digital Engagement Engine™. This technology provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, which creates digital experiences that accelerate an audience from awareness to action – driving growth.

Electronic Servitor Publication Network’s services are designed to drive growth for both established and developing organizations. Through the optimization of digital interactions within current and new communities, the Digital Engagement Engine™ ensures that client content is relevant, reaches the right audience, and connects with the intended person at the right time.

The company calls it ‘Growth as a Service’.

Client implementation is nearly effortless, since the solution is completely managed by the Electronic Servitor Publication Network team. This business model allows clients to focus on their brands, core product offerings, and content creation, while the company manages the technology and outcome.

The company is headquartered in Minneapolis, Minnesota.


Electronic Servitor Publication Network’s Digital Engagement Engine™ utilizes a combination of automation, unique data management, and a modern workflow built on a microservices architecture to achieve greater reach and lift. Using sophisticated data analysis and smart technology, the Digital Engagement Engine™ provides companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers and revenue streams.

The Digital Engagement Engine™ isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.

Market Outlook

According to a report by, an award-winning market research firm, the global customer engagement solutions market was estimated at $19.3 billion in 2022 and is forecast to grow to $32.2 billion by 2027, achieving a CAGR of 10.8% during the forecast period.

The report notes that these engagement solutions are vital to companies seeking to widen their customer bases, reduce customer churn rates and increase customer retention. These perceived benefits of customer engagement solutions are likely to drive their growing adoption around the globe during the forecast period, according to the report.

Management Team

Peter Hager is President and CEO of Electronic Servitor. He joined the company from Pointward Inc., a medtech customer engagement agency that provided solutions to drive market entry, growth, and commercialization for Fortune 500 health care brands and medtech startups. He has founded and managed multiple technology, professional services and medtech organizations throughout his career. Mr. Hager holds a bachelor’s degree from Macalester College in St. Paul, Minnesota, with concentrations in economics and psychology.

Jim Kellogg is CFO of Electronic Servitor. He has served as the principal of J. Kellogg & Company Inc., a business and tax consultant, since 2005. He has provided legal support to clients’ business valuations, business interruption and divorce property valuations. He has worked as a professional tax adviser since 1983. Mr. Kellogg obtained his JD with emphasis on taxation from Western State University College of Law and was certified as a financial planner by the College for Financial Planning in 1990.

Thomas (Denny) Spruce, RPh, is COO of Electronic Servitor. He oversees company infrastructure, regulatory reporting, and strategic partner relationships, among other roles and responsibilities. He joined the company in March 2022 and, since that time, has implemented foundational support processes, developed contractual relationships with service providers, managed financial and regulatory reporting and overseen contract development and management with the legal team. Mr. Spruce obtained a BS in Pharmacy from the University of Arkansas.

Electronic Servitor Publication Network Inc. (XESP), closed Friday's trading session at $0.055, even for the day. The average volume for the last 3 months is 30,000 and the stock's 52-week low/high is $0.03/$0.2245.

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX) is conducting its Phase 1/2 Acclaim-1 clinical trial evaluating the safety and efficacy of combining REQORSA(R), the company's innovative drug candidate, in combination with Tagrisso(R) in patients with advanced EGFR mutant non-small cell lung cancer ("NSCLC") who have experienced disease progression after previous treatments. "REQORSA Immunogene Therapy represents a potentially groundbreaking experimental drug that harnesses the power of genetic medicine to combat NSCLC," a recent article explains. "During the Phase 1 portion of the clinical trial, the primary emphasis is on evaluating the safety of the treatment.

However, the findings also have revealed promising efficacy results. One patient previously treated with standard-of-care therapies such as osimertinib had a partial remission (‘PR') by investigator evaluation and treatment is ongoing after 16 cycles, which is approximately 10.5 months. Another patient previously treated with osimertinib has stable disease and treatment is ongoing after 14 cycles, or approximately 9 months. The extended and ongoing progression free survival (‘PFS') of each of these patients is significantly greater than the median PFS observed from treatment with osimertinib alone in this treatment setting in several prior clinical trials and is consistent with long-term PFS seen in prior clinical trials of REQORSA. These findings underscore the potential of REQORSA in reshaping the landscape of non-small cell lung cancer."

To view the full article, visit

Genprex Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Friday's trading session at $0.8238, off by 3.1052%, on 187,420 volume. The average volume for the last 3 months is 187,420 and the stock's 52-week low/high is $0.7225/$2.67.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, has released a letter to its shareholders designed to address the decrease in the company's share price. The letter noted that earlier this week, the company's common stock closed at $0.32 per share, down 90% since the end of March. The company currently trades at a discount to its current cash position of $135 million or $0.38 per share. The letter noted several key factors, including $86.7 million of cash available to operations and $0.68 of cash value per share as of March 31, 2023, and the completion of two acquisitions, which has added valuable, unencumbered assets to the company's balance sheet. "Despite the decline in stock price, management believes we are in position to meet the previously announced objectives for moving first into the production and then sale of our Class 3 commercial vehicles during the quarter ending Sept. 30, 2023," the company stated in the shareholder letter. "To date, the company has filed over 200 U.S. and international patent applications, with 90 patents granted to date, related to vehicle design, technology, safety and convenience features in support of the Mullen FIVE consumer vehicle program. The company has received $279 million in purchase orders from Randy Marion Automotive Group for Mullen Class 1 and Class 3 EV vans and trucks. Randy Marion, based in North Carolina, is one of the largest commercial vehicle dealer groups in the U.S."

To view the full press release, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Friday's trading session at $0.229, off by 12.4618%, on 293,832,412 volume. The average volume for the last 3 months is 293.832M and the stock's 52-week low/high is $0.201/$42.75.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.